Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Affibody, Alnylam, Anixa, Aravive, Astellas, Astrazeneca, Atreca, Bausch + Lomb, Beigene, Bioage Labs, Biocon, Bixink, Catalent, Celltrion, Clearside, Cytodyn, Daewoong, Edigene, Eli Lilly, Evergreenhealth, Fujifilm Diosynth, Generex, Gilead, Harbour, Heat Biologics, IGM Biosciences, Inovio, Insilico, J&J, Junshi, Lonza, Marinomed, Moderna, Mylan, Nanoviricides, Noachis Terra, Ology, Ontochem, Oragenics, Oxford Biodynamics, Pneumagen, Proteogenix, Puma, Recce, Sarepta, Secarna, Shionogi, Stabilitech, Taisho, Takis, Teva, Union, Vaxart, Verndari, Vir, Viralclear, Vistagen, Wuxi, Xbiotech USA, Xortx.
Quarterly snapshots from biopharma companies with marketed products, including: Insmed.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Pluristem.
New hires and promotions in the biopharma industry in Asia-Pacific, including: Tessa Therapeutics.
The latest global regulatory news, changes and updates affecting biopharma, including: Chugai, Pfizer, Roche, Therapeutic Goods Administration.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aridis, Athersys, Biontech, Calcimedica, Chimerix, Cromos, Eiger, Eli Lilly, Geneone Life Science, Gilead Sciences, Gracell, I-Mab, Innate, Innovent, Inovio, Janssen, Lupin, Mesoblast, Morphosys, Novartis, Pfizer, R-Pharm, Synairgen, Yuhan.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Akarx, Algernon, Ascentage, Capricor, Combioxin, Cytodyn, Junshi, Moderna, Pharmamar, Remegen, Shionogi, Telix.